NIAGADS is the National Institute on Aging (NIA) designated national data repository for human genetics research on Alzheimer's Disease and related dementia (ADRD). NIAGADS maintains a high-quality data collection for ADRD genetic/genomic research and supports genetics data production and analysis. NIAGADS hosts whole genome and exome sequence data from the Alzheimer's Disease Sequencing Project (ADSP) and other genotype/phenotype data, encompassing 209,000 samples. NIAGADS shares these data with hundreds of research groups around the world via the Data Sharing Service, a FISMA moderate compliant cloud-based platform that fully supports the NIH Genome Data Sharing Policy. NIAGADS Open Access consists of multiple knowledge bases with genome-wide association summary statistics and rich annotations on the biological significance of genetic variants and genes across the human genome. NIAGADS stands as a keystone in promoting collaborations to advance the understanding and treatment of Alzheimer's disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11483014 | PMC |
| http://dx.doi.org/10.1101/2024.10.07.24315029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Multifunctional Ru-Re Complex for Photodynamic Therapy and CO-Mediated Therapeutics in Alzheimer's Disease.
Chemistry
December 2024
National Taiwan University Hospital, Immune Research Core, Department of Medical Research, TAIWAN.
The development of multifunctional therapeutic agents is crucial for addressing complex diseases such as Alzheimer's disease. Herein, we report a ruthenium-rhenium (Ru-Re) complex that combines photodynamic therapy (PDT) and carbon monoxide (CO) generation capabilities. The Ru-Re complex shows promising photophysical property and significant therapeutic potential.
View Article and Find Full Text PDFMechanisms and clinical applications of palmitoylethanolamide (PEA) in the treatment of neuropathic pain.
Inflammopharmacology
December 2024
Department of Research and Development, First Floor, Molecules Biolabs Private Limited, Commercial Building Kinfra, 3/634Konoor Road, Muringur, Vadakkummuri, Koratty, Mukundapuram, Thrissur, Kerala, 680309, India.
Palmitoylethanolamide (PEA) is emerging as a promising therapeutic agent for neuropathic and other pain-related conditions. This naturally occurring fatty acid has drawn interest because of its ability to regulate pain and inflammation. Initially identified in food sources, PEA has been the subject of extensive research to elucidate its properties, efficacy, and clinical applications.
View Article and Find Full Text PDFRASGEF1C as a novel prognostic biomarker for LUAD.
Discov Oncol
December 2024
Department of Thoracic Surgery, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, No. 1500 Zhouyuan Road, Pudong New Area, Shanghai, China.
Lung adenocarcinoma (LUAD) is a common histologic lung cancer with high morbidity and mortality, and most patients have distant metastases at diagnosis. RasGEF Domain Family Member 1C (RASGEF1C) could regulated Alzheimer's disease. However, its function in various cancers, including LUAD, is poorly understood.
View Article and Find Full Text PDFCorrection: Pyroptosis in Alzheimer's disease: cell type‑specific activation in microglia, astrocytes and neurons.
Acta Neuropathol
December 2024
Laboratory for Neuropathology, Department of Imaging and Pathology, Leuven Brain Institute (LBI), KU Leuven (University of Leuven), O&N IV Herestraat 49, Bus 1032, 3000, Leuven, Belgium.
A Self-Reinforced "Microglia Energy Modulator" for Synergistic Amyloid-β Clearance in Alzheimer's Disease Model.
Angew Chem Int Ed Engl
December 2024
Nanyang Technological University, School of Chemistry, Chemical Engineering and Biotechnology, 21 Nanyang Link, 637371, Singapore, SINGAPORE.
Microglial phagocytosis is a highly energy-consuming process that plays critical roles in clearing neurotoxic amyloid-β (Aβ) in Alzheimer's disease (AD). However, microglial metabolism is defective overall in AD, thereby undermining microglial phagocytic functions. Herein, we repurpose the existing antineoplastic drug lonidamine (LND) conjugated with hollow mesoporous Prussian blue (HMPB) as a "microglial energy modulator" (termed LND@HMPB-T7) for safe and synergistic Aβ clearance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!